argenex (NASDAQ:ARGX) Stock Purchase Revealed by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of argenex SE (NASDAQ:ARGX). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $15,001 and $50,000 in argenex stock on October 14th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.

argenex Price Performance

Shares of ARGX traded up $3.75 during midday trading on Thursday, hitting $981.33. The stock had a trading volume of 449,412 shares, compared to its average volume of 353,577. The company has a 50 day simple moving average of $927.22 and a two-hundred day simple moving average of $859.56. argenex SE has a twelve month low of $661.85 and a twelve month high of $1,072.75. The firm has a market cap of $61.72 billion, a price-to-earnings ratio of 34.24, a price-to-earnings-growth ratio of 0.90 and a beta of 0.48.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Friday, October 23rd. The company reported $7.80 earnings per share for the quarter, topping the consensus estimate of $7.44 by $0.36. The company had revenue of $1.75 billion during the quarter. argenex had a return on equity of 47.70% and a net margin of 31.66%. Analysts forecast that argenex SE will post 28.41 EPS for the current fiscal year.

Institutional Trading of argenex

Several large investors have recently made changes to their positions in ARGX. Eastern Bank bought a new stake in argenex during the second quarter worth $32,000. Axiom Investment Management LLC bought a new stake in shares of argenex during the 1st quarter valued at approximately $50,000. Harbour Investments Inc. lifted its stake in argenex by 966.7% in the 3rd quarter. Harbour Investments Inc. now owns 64 shares of the company’s stock valued at $62,000 after purchasing an additional 58 shares during the last quarter. Richardson Financial Services Inc. acquired a new stake in argenex in the third quarter valued at approximately $66,000. Finally, Bogart Wealth LLC lifted its stake in shares of argenex by 2,500.0% in the 3rd quarter. Bogart Wealth LLC now owns 78 shares of the company’s stock valued at $75,000 after acquiring an additional 75 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

ARGX has been the topic of a number of research reports. Truist Financial boosted their price objective on shares of argenex from $1,030.00 to $1,095.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of argenex in a report on Wednesday, August 5th. Citizens Jmp upped their price objective on argenex from $932.00 to $1,200.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 18th. Sanford C. Bernstein reissued a “buy” rating on shares of argenex in a research note on Thursday, October 8th. Finally, Barclays reaffirmed a “buy” rating on shares of argenex in a research report on Monday, September 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,158.76.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About argenex

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.